Joyce A. O’Shaughnessy, MD
Since triple-negative breast cancer (TNBC) is resistant to multiple therapies, physicians have little flexibility for treatment options. However, anticipation is building for potential alternatives. “Right now, for TNBC, chemotherapy is our only option,” said Joyce A. O’Shaughnessy, MD, co-chair of Breast Cancer Research and the chair of Breast Cancer Prevention Research at Baylor- Sammons Cancer Center in Dallas, Texas. “That’s about to change very soon with the likely availability of atezolizumab [Tecentriq].”
East, held by Physicians’ Education Resource® in New York, O’Shaughnessy walked her audience through the most recent findings and ongoing research in the field, focusing on agents inhibiting the PI3K/AKT signaling pathway and the ADC sacituzumab govitecan.
FIRST-LINE AKT INHIBITORS IMPROVE PFS
The PI3K/AKT/mTOR signaling pathway is frequently activated in TNBC. Furthermore, deficient PTEN expression is often found in TNBC and is associated with a higher degree of PI3K pathway activation.
... to read the full story